FIP1L1-PDGFRα alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib

Chinese Medical Journal

Volumn 121, Issue 10, 2008, Pages 867-873

  Wang, Lin Na ^a   Pan, Qin ^a   Fu, Jian Fei ^a   Shi, Jing Yi ^a   Jin, Jie ^b   Li, Jun Ming ^a   Hu, Jiong ^a   Zhao, Wei Li ^a   Chen, Zhu ^a   Chen, Sai Juan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Chronic eosinophilic leukemia; FIP1L1 PDGFR ; Imatinib mesylate; Myeloproliferative disease; Tyrosine kinase

Indexed keywords

ABELSON KINASE; ALPHA INTERFERON; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; JANUS KINASE 2; PHENYLALANINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; PROTEIN FIP1L1; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR; VALINE; ANTINEOPLASTIC AGENT; CLEAVAGE AND POLYADENYLATION SPECIFICITY FACTOR; FGFR1 PROTEIN, HUMAN; FIP1L1 PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; CARCINOGENESIS; CHROMOSOME 4Q; CHROMOSOME DELETION; CHRONIC LEUKEMIA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG WITHDRAWAL; EOSINOPHILIA; EOSINOPHILIC LEUKEMIA; EXON; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE FREQUENCY; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEPATOSPLENOMEGALY; HUMAN; LEUKEMIA REMISSION; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PROTEIN FAMILY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; THROMBOCYTOPENIA; TISSUE INJURY; TREATMENT OUTCOME; CHRONIC DISEASE; DISEASE COURSE; GENETICS; GENOTYPE; HYPEREOSINOPHILIC SYNDROME; IN SITU HYBRIDIZATION; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENOTYPE; HUMANS; HYPEREOSINOPHILIC SYNDROME; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; MRNA CLEAVAGE AND POLYADENYLATION FACTORS; MUTATION; ONCOGENE PROTEINS V-ABL; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PIPERAZINES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 51149106522     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00029330-200805020-00001     Document Type: Article

References (19)

1. Klion AD. Recent advances in the diagnosis and treatment of hypereosinophilic syndromes. Hematology Am Soc Hematol Educ Program 2005: 209-214.
2. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660-4666.
3. Roche-Lestienne C, Lepers S, Soenen-Cornu V, Kahn JE, Lai JL, Hachulla E, et al. Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics. Leukemia 2005; 19: 792-798.
4. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
5. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
6. Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG. The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr Opin Hematol 2004; 11: 51-57.
7. Gotlib J, Cools J, Malone JM 3rd, Schrier SL, Gilliland DG, Coutre SE. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103: 2879-2891.
8. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) 1975; 54: 1-27.
9. Shaffer LG., Tommerup N. ISCN 2005: An international system for human cytogenetic nomenclature (Cytogenetic & Genome Research). Basel: S Karger Pub; 2005: 1-130.
10. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103: 473-478.
11. Miyaso H, Okumura M, Kondo S, Higashide S, Miyajima H, Imaizumi K. An intronic splicing enhancer element in survival motor neuron (SMN) pre-mRNA. J Biol Chem 2003; 278: 15825-15831.
12. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001; 109: 121-124.
13. Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood 2004; 104: 3038-3045.
14. Vandenberghe P, Wlodarska I, Michaux L, Zachee P, Boogaerts M, Vanstraelen D, et al. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias. Leukemia 2004; 18: 734-742.
15. Yamada Y, Rothenberg ME, Lee AW, Akei HS, Brandt EB, Williams DA, et al. The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. Blood 2006; 107: 4071-4079.
16. Bock O, Loch G, Busche G, von Wasielewski R, Schlue J, Kreipe H. Aberrant expression of platelet-derived growth factor (PDGF) and PDGF receptor-alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis. Haematologica 2005; 90: 133-134.
17. Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H, et al. Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis. Am J Hematol 2003; 74: 238-242.
18. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
19. Chiara F, Bishayee S, Heldin CH, Demoulin JB. Autoinhibition of the platelet-derived growth factor beta-receptor tyrosine kinase bv its C-terminal tail. J Biol Chem 2004; 279: 19732-19738.